Financing channel feed – Endpoints News

Financing channel feed

A startup backed by Nobel winner David Baker takes an AI twist on antibodies

6 months ago

Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain

6 months ago

Pathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AI

6 months ago

Synaffix, industry's ADC partner of choice, spins out a startup pipeline

6 months ago

Septerna bags $288M upsized IPO for GPCR drugs

7 months ago

Sanofi backs fibrosis biotech Agomab as it raises $89M Series D

7 months ago

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

7 months ago

Radiopharma startups stay hot as Alpha-9 bags $175M Series C

7 months ago

Life sciences investor Dimension seeks to raise $500M second fund

7 months ago

Houston startup March Biosciences raises $28M to get CAR-T into Phase 2

7 months ago

Be Bio raises $82M to fund work on B cell therapy in hemophilia B

7 months ago

AvenCell gets $112M to build switchable CAR-T therapies for ‘the last frontier’ of blood cancers

7 months ago

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

7 months ago

Septerna outlines $157M IPO after entering the clinic with GPCR pipeline

7 months ago

Former Karuna crew quickly assembles $225M for next neuro bet at Seaport

7 months ago

Shanghai biotech’s VEGF bispecific enters Phase 1 trial in China

7 months ago

Secretive Treeline Biosciences discloses $421M financing in filing

7 months ago

Exclusive: Terray raises $120M for its AI ways of designing molecules

7 months ago

Life sciences investor KdT Ventures raises $100M fund to back new startups

7 months ago

Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus

7 months ago

Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex

7 months ago

Exclusive: Biotech tools company raises $75M for protein manufacturing tech

7 months ago

Forbion raises €2.1B for two new biotech funds after series of company exits

7 months ago

Mark Pruzanski gets another shot at MASH, joining as chair of Inventiva as it gets ‘much-needed funding’

7 months ago

First page Previous page 5 6 789 10 11 Next page Last page